Hansa’s partner Genethon initiates a phase 2 study based on Imlifidase as a pre-treatment ahead of G...
Redeye is encouraged by the significant margin improvement achieved in the second quarter.
Redeye updates on Maximum Entertainment following its Q3-results which were weaker than expected.
Redeye leaves a comment following the promising recent interim data from Faron’s BEXMAB study and in...
The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) ...
Minor estimate revisions Subscription business performed well.
After a soft Q3, PMD Device Solutions (“PMD”) is still aiming for a cash break-even by late 2024 or ...
Sales of SEK 49m -38% q-o-q, EBIT back to negative at SEK -8m We lower FY'24/25e-FY'26/27e sales by ...
ODI Pharma AB:s (”ODI Pharma” or the ”Company”) latest quarter was affected by import restrictions i...
Ytterst positivt studieresultat Efter kvartalets slut meddelade bolaget att fas 1b-studien med STA36...
The US company is both a health insurance and a health care service provider covering more than 10m ...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har under och efter utgången av...
Solwers posted Q3 2024 revenue growth of 21% y/y, entirely driven by acquisitions.
Redeye comments on Gapwaves' joint venture agreement with Bosch and revised its estimates and fair v...
Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controll...
Divests four service-oriented Infra units for SEK 714m consideration Accelerates transition to highe...
Irisity AB (”Irisity” or ”the Company”) announced, on the 28th of November, the outcome of the right...
Tangiamo Touch Technology (”Tangiamo” eller ”bolaget”) publicerade den 29 november 2024 bolagets del...
Q3 sales are down by 12% compared with Q3 2024 and by some 35% compared with the previous quarter at...
Bid of DKK 16.5/share is a ~110% premium to last close Several major shareholders intend to accept t...
